Track topics on Twitter Track topics that are important to you
Under the deal, Vir can non-exclusively access Xencor’s Xtend Fc technology to expand the half-life of novel antibodies, which are being assessed as potential treatments for patients with
The post Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19 appeared first on Pharmaceutical Business review.NEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...